Latest News and Press Releases

DISCO signs exclusive deal with Amgen to develop cancer therapies from its surfaceome platform; deal worth up to $618M plus royalties.

Hummingbird Bioscience today announced that the first patient has been dosed in a Phase I clinical trial of HMBD-501.

DISCO Pharmaceuticals appoints biotech leader Mark Manfredi as CEO and raises €36M to advance surfaceome-targeted ADC therapies for hard-to-treat tumors

Berlin, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tacalyx, a privately held biotech company focused on developing novel TACA (Tumour Associated Carbohydrate Antigens) cancer therapies, announces...

- FDA requests additional information on a formulation component - HUNTSVILLE, AL, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage...

Adcytherix lève 105 millions d’euros pour accélérer le développement de son portefeuille d‘anticorps conjugués de nouvelle génération intégrant de nouveaux agents cytotoxiques. Le tour de table est...

Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led by Bpifrance with co-leads Kurma Partners, Andera...

Medicovestor wins First Place at the 2025 Next Star Biomedical Competition in Boston for groundbreaking ADC platforms targeting pancreatic & ovarian cancer

HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...

Austin, TX, USA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Targeted Drug Delivery Market Size, Trends and Insights By Technology...